<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01843556</url>
  </required_header>
  <id_info>
    <org_study_id>E2022-J081-003</org_study_id>
    <nct_id>NCT01843556</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study of E2022 Tape Formulation for Different Application Sites and Intervals in Japanese Healthy Elderly Males</brief_title>
  <official_title>A Phase 1 Study of E2022 Tape Formulation for Different Application Sites and Intervals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <brief_summary>
    <textblock>
      A phase 1 study of E2022 tape formulation in healthy elderly males to evaluate the safety and
      pharmacokinetics.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number and frequency of adverse events</measure>
    <time_frame>168 hours after the end of application</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximal Drug Concentration (CMax)</measure>
    <time_frame>216 hours after the end of application</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve (AUC)</measure>
    <time_frame>216 hours after the end of application</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax)</measure>
    <time_frame>216 hours after the end of application</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Decay Half-Life (t1/2)</measure>
    <time_frame>216 hours after the end of application</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Healthy Elderly Male</condition>
  <arm_group>
    <arm_group_label>E2022 Tape Formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E2022 Tape Formulation</intervention_name>
    <description>E2022 tape formulation applied to different application sites and at different intervals in Japanese healthy elderly males</description>
    <arm_group_label>E2022 Tape Formulation</arm_group_label>
    <other_name>Donepezil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Male non-smokers (not smoking at least 4 weeks before Period 1) aged 65 years or older
             at informed consent

          2. BMI at screening is 18.5 kg/m2 or above - below 28.0 kg/m2

          3. Written informed consent

          4. Given full explanation of this study and is willing to and able to comply with the
             protocol requirements

        Exclusion criteria:

          1. Have a current or past history of disorder requiring medical treatment within 8 weeks
             before the first application or infection within 4 weeks before the first application

          2. Have a disorder within 4 weeks before the first application which affects the
             evaluation of study drug such as psychiatric, gastrointestinal, hepatic, renal,
             respiratory, endocrinological, hematological, neurological or cardiovascular system,
             or congenital metabolic abnormality

          3. Have a history of gastrointestinal surgery (e.g., liver, kidney, digestive tract)
             which affects the pharmacokinetics of study drug,

          4. Have a history of treatment-requiring drug or food allergy or seasonal allergy at
             screening

          5. Had caffeine-containing food or drink or alcohol within 72 hours before study drug
             application in Period I

          6. Had nutritional supplements, herbal preparations (including oriental medicines) or
             others (e.g., grapefruit-containing food or beverage) which may affect drug
             metabolizing enzymes and transporters, within 1 weeks before Period I

          7. Have used liquid products (including cosmetics) on study application sites (back,
             upper limb, chest), patch, tape or bandage, within 4 weeks before Period 1

          8. Present or past clinical signs of skin hypersensitivity to topical product or atopic
             dermatitis

          9. Excessively hairy or have shaved at application sites (back, upper limb, chest) within
             4 weeks before Period 1

         10. Eczema, dermatitis, abnormal pigmentation, injury, or scar at application sites which
             may affect the evaluation of skin symptoms
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hidetaka Hiramatsu</last_name>
    <role>Study Director</role>
    <affiliation>Eisai Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Kagoshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2013</study_first_submitted>
  <study_first_submitted_qc>April 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2013</study_first_posted>
  <last_update_submitted>February 17, 2014</last_update_submitted>
  <last_update_submitted_qc>February 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

